secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K/A
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001213900-23-087115
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.03
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma changes fiscal year to June 30, effective Sept 29, 2023
-----------------------------------------------------------------------------

- Fiscal year end changed from December 31 to June 30, effective upon close of business combination.
- Change aligns fiscal year with Estrella Biopharma, the accounting acquirer in the combination.
- First fiscal year under new end will be the period ending June 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390023087115/0001213900-23-087115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390023087115/ea188438-8ka1_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-087115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer